Marker Therapeutics: Funding, Investors & Team (Oct 2026)
Marker Therapeutics is a clinical stage immuno-oncology company focused on developing adoptive non-gene modified T cell therapies for the treatment of hematologic malignancies such as Acute Myeloid Leukemia, Lymphoma, and Multiple Myeloma. Marker’s MultiTAA technology selectively expands non-engineered T cells, enhancing them with the ability to kill tumor cells by targeting multiple tumor-associated antigens simultaneously to prevent immune escape and generate durable immunity. Patient/donor T cells are not genetically modified and therefore the cost of generating Marker’s therapies is significantly reduced.
Marker Therapeutics has raised $40.1M across 3 funding rounds on record, the most recent an undisclosed round of $25.0M announced in Dec 2022.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Marker Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2022.
Marker Therapeutics Funding Rounds
Marker Therapeutics raised $13.1M in a Grant announced in Aug 2021.
1.1 years later, a Grant of $2.0M was announced in Sep 2022.
3 months later, an undisclosed round of $25.0M was announced in Dec 2022.
Marker Therapeutics Founders and Leadership Team
Contact details for the Marker Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →Marker Therapeutics Funding Compared to Other Biotechnology Startups
Marker Therapeutics' latest round of $25.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Marker Therapeutics in Biotechnology and Minneapolis
Companies Similar to Marker Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Marker Therapeutics Funding FAQs
What does Marker Therapeutics do?
Marker Therapeutics is a clinical stage immuno-oncology company focused on developing adoptive non-gene modified T cell therapies for the treatment of hematologic malignancies such as Acute Myeloid Leukemia, Lymphoma, and Multiple Myeloma. Marker’s MultiTAA technology selectively expands non-engineered T cells, enhancing them with the ability to kill tumor cells by targeting multiple tumor-associated antigens simultaneously to prevent immune escape and generate durable immunity. Patient/donor T cells are not genetically modified and therefore the cost of generating Marker’s therapies is significantly reduced.
How much funding has Marker Therapeutics raised?
Marker Therapeutics has raised $40.1M across 3 rounds on record. The most recent is an undisclosed round of $25.0M announced in Dec 2022.
When did Marker Therapeutics last raise funding?
Marker Therapeutics' most recent funding round on record is an undisclosed round of $25.0M, announced in Dec 2022.
Who is the CEO of Marker Therapeutics?
John Wilson is listed as CEO at Marker Therapeutics.
Where is Marker Therapeutics headquartered?
Marker Therapeutics is based in Minneapolis, Minnesota, United States.
How many employees does Marker Therapeutics have?
Marker Therapeutics is in the 11-50 employee band.
How does Marker Therapeutics' funding compare to other Biotechnology startups?
Marker Therapeutics' latest round of $25.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Marker Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Marker Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.